Listen

Add to my selection

SPINRAZA

Medicine - Posted on Jul 10 2024

Active substance (DCI)

nusinersen

history (3)

7/3/24

SPINRAZA (nusinersen) - Spinal muscular atrophy

Summary of opinion Favourable opinion for reimbursement: “in pre-symptomatic paediatric patients with genetically diagnosed ...

CAV :
54321

icône flèche
7/22/20

SPINRAZA

New assessment. Favourable opinion for reimbursement in the treatment of pre-symptomatic infants and children with genetical...

CAV :
54321

icône flèche
1/31/18

SPINRAZA (nusinersen), antisense oligonucleotide

High clinical benefit for 5q spinal muscular atrophy types I and II and moderate clinical added value for the therapeutic st...

CAV :
54321

icône flèche

Technical information

ATC code

M09AX07

Manufacturer

BIOGEN FRANCE SAS

Presentation

SPINRAZA 12 mg, solution injectable (code CIS : 65599882)
1 flacon(s) en verre de 5 ml (CIP : 34009 550 331 5 8)

All our publications

Congenital, genetic and rare diseases

Health economics

Neurodegenerative diseases

Neuromuscular diseases